No Spotlight Needed

Sheetal Prasad

No Spotlight Needed is a leadership podcast that explores the human stories behind extraordinary executives. Through candid, in-depth conversations, CEOs and senior executives reveal the values, formative experiences, and decision-making frameworks that rarely make headlines but leave a lasting impact. These stories highlight critical lessons and management insights from today’s most effective business leaders. Whether you’re an aspiring leader, a seasoned executive, or simply curious about the intersection of character and business, this podcast offers clarity, humility, and practical wisdom

Episodes

  1. 2d ago

    The Quiet Leader Who Built a $130B Health Company

    Paul Perreault led CSL for a decade, growing it into a $130 billion market cap company and the world's leading manufacturer of plasma derived therapies. He started as a field sales rep, planned to become a priest, and carried one lesson through his entire career: never confuse your job title with who you are. In this conversation Paul talks about the generalist philosophy that shaped his leadership, the capital discipline that made CSL different from every other biotech, the three major acquisitions that defined his tenure including the one that did not play out as expected, what it was like navigating Covid as a company deep in plasma collection and vaccine manufacturing, and when he knew it was time to leave a company before complacency set in. Direct, patient, and completely uninterested in the spotlight. Let's connect: LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneeded Timestamps: 0:00 - Teaser: never confuse your job with who you are 0:50 - Introduction: Paul Perreault and CSL 2:10 - The Detour CEO: what detour means in a career 3:54 - The seminary: why the structure forced him to leave 6:08 - You can be CEO of the largest company and still take out the trash 6:39 - Growing up the second of eight kids and what it taught him 7:23 - Starting as a field rep and planning to retire as one 8:09 - The value of being a generalist in a world that rewards specialists 9:27 - The Wharton simulation: why diverse teams build better businesses 12:46 - His father worked at the same company: what he learned from him 13:52 - When is the right time to leave? The complacency signal 15:33 - Once you hit the peak it is all downhill 16:09 - Joining Centeon: the leap from a large company to a small one 16:31 - Why the plasma business is completely different from pharma and biotech 18:31 - 200 days from collection to product on the market 19:19 - Why CSL required extreme capital discipline that pharma never does 20:36 - Becoming CEO in 2013 and the decision to accelerate plasma center growth 21:08 - What immune deficiency actually looks like for patients 24:07 - Growing plasma centers: the demand was always there, the supply was not 27:20 - The flu vaccine acquisition: everybody said he was crazy 30:57 - They all said I was crazy. Less than five years later: $1B in revenue and 20% EBITDA. 32:09 - The gene therapy deal: why he waited until 2020 to enter the space 33:46 - Why he went after hemophilia B when everyone else chased hemophilia A 35:31 - There is a lot of money in a cure: the economics of the $3.5M treatment 36:39 - The scoreboard was never the game plan 37:09 - The $11.7B Vifor acquisition: the deal that did not go as expected 38:30 - The opportunity was right. Maybe the price was not. 42:43 - Nobody from the company had ever visited the plants. He showed up anyway. 44:16 - We were not serial acquirers. Three deals in ten years. 45:08 - Covid: screaming for a vaccine, then criticizing it when side effects emerged 46:42 - The product was not rushed. The funding just moved faster. 47:30 - Getting three competitors together to collect convalescent plasma 49:09 - Feeling helpless in Switzerland while his teams showed up every day 51:10 - Covid was the macro example of something leaders face every single day 52:39 - Sustaining mental, physical, business, and family health all at once 52:53 - Closing reflections

    53 min

  2. May 29

    How This Company Went From Nothing To $4 Billion!

    Kevin Sayer spent 15 years as CEO of Dexcom, growing it from a niche startup into a $4 billion company that created the continuous glucose monitoring industry from scratch. In this episode of No Spotlight Needed, he sits down with Sheetal to tell the whole story: the early bets, the hard lessons, the bold moves, and what it really took to build something that has saved lives around the world. Kevin opens up about his recent cancer diagnosis and recovery, the toughest quarter of his career in 2024, why he delayed the G4 launch and tanked the stock price, the Super Bowl ad decision, the Google partnership, how Dexcom responded to the GLP-1 threat, and why he stepped down on his own terms. This is a masterclass in long-term thinking, accountability, and building a business you believe in. Let's connect: LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps: 0:00 - Teaser 0:53 - Introducing Kevin Sayer 2:30 - Cancer diagnosis and recovery 3:34 - The hardest quarter: 2024 4:33 - Accountability, no excuses 7:10 - Meeting the commercial team every day 7:38 - Identifying who your customer really is 10:02 - Growing up in Idaho: the Jeep dealership 11:04 - Never judge anyone by what they're wearing 12:28 - Driving car lots at night: customer retention 13:40 - CFO of Mini Med under Alfred Mann 14:07 - He lied about the $10M raise 15:16 - What Alfred Mann taught him: tenacity 16:09 - Someone gave us a chance we didn't deserve 16:27 - Hospital bed visit: implantable pump under the covers 17:37 - Mini Med acquired by Medtronic for $3.5B 19:58 - Never run a business to sell it 21:33 - Specialty Labs, Biosensors, the years in between 22:18 - His wife: most unhappy I've ever seen you 23:10 - Nobody offered him an operating role 25:14 - Joining Terry Gregg and moving to San Diego 26:11 - Terry's recruiting lesson: how do you want to do this? 27:22 - What made Terry Gregg a remarkable leader 30:35 - G4: first decision drove the stock from 17 to 6 31:36 - Not good enough, and they know how to fix it 32:19 - Daily engineer meetings and the October 15th deadline 33:04 - Why G4 was the pivotal moment 35:04 - Scaling from $76M to $600M 35:38 - Technology first, then commercial, then manufacturing 38:27 - Going to the phone and data sharing 40:35 - The email from the law student in Topeka 44:29 - The Super Bowl ad debate: $5.5M for 30 seconds 44:55 - His father's last call before he passed 46:52 - Text from UnitedHealthcare: this is very cool 48:00 - Second Super Bowl ad for G7: $7M 48:42 - Stelo and going direct to consumer 49:08 - The Google partnership 51:00 - Partnerships are not marriages 51:54 - Embracing GLP-1s instead of fearing them 55:32 - Stepping down before anyone pushed him out 55:54 - Most proud of: creating an industry from scratch

    57 min

  3. May 22

    Perfect Chemistry: The Untold Story Behind the Hepatitis C Cure

    What does a career look like when one chapter ends with an $11 billion acquisition, the next involves FBI visits and death threats, and the third ends with a devastating phase 3 failure that nobody saw coming?Dr. Michelle Berrey has lived all three. Over 15 years as a chief medical officer and CEO at Pharmasset, Chimerix, and Intercept Pharmaceuticals, she helped develop a cure for hepatitis C, navigated a national social media firestorm over a dying child, led a company through the Ebola outbreak, and faced a phase 3 failure that dropped the stock 90% overnight.In this conversation, she talks through every chapter with rare honesty, including what it takes to build a career-long relationship with the FDA, how she became CEO in 48 hours without asking for the job, and why the most important thing she ever learned was not to define yourself by your most recent result.Let's connect:LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps:0:00 - Teaser: death threats, the FBI, an $11B deal, and a 90% stock drop0:39 - Introduction: Dr. Michelle Berrey and her three biotech chapters2:26 - Three very different chapters: what have you learned?3:08 - Why Big Pharma drove her nuts and biotech set her free4:04 - Fail fast and focus: the operating philosophy that defined her career5:37 - Training during the HIV crisis at University of Washington6:12 - Standing outside bathhouses to understand transmission7:03 - Running her first clinical trials and learning to pay attention to outliers7:47 - Moving to GSK and using it like a university10:01 - Raising two kids as a single mom while building a career at Glaxo11:37 - The decision to leave Big Pharma for something more entrepreneurial12:43 - Joining Pharmasset as CMO: no committees, never looked back13:27 - The Hepatitis B phase three and the safety signal from Korea15:05 - Patient safety above everything: pivoting to Hep C16:44 - From the very first three patients, the viral load just kept dropping17:39 - The interferon question and why they went to New Zealand20:58 - Gilead approaches with an $11 billion offer at a 90% premium21:28 - Did you want to sell? "I didn't. It was my baby."22:23 - "It warms my heart every time I meet someone whose life was changed"22:36 - What made Pharmasset almost perfect: the chemistry and the prodrug23:41 - A fairytale ending on two fronts: the acquisition and a love story29:41 - The Josh Hardy story: a sick child and 80,000 tweets31:17 - "We had the FBI come in. We were getting death threats. The drug worked."32:02 - Named CEO in 48 hours: a field promotion she never asked for33:43 - The team that made the CEO role work35:49 - Six months later: Ebola and 2am calls with the FDA37:22 - A career-long relationship with the FDA built on trust and urgency39:09 - The SUPPRESS trial: December 15, 2015. Did not hit statistical significance.39:37 - Worse outcomes in the drug arm. "What does statistics matter when you're talking about lives."40:03 - Weeks of around the clock analysis: a protocol issue, not the drug40:36 - Stock falls 90%. A third of employees let go.42:12 - "The drug is not you"43:05 - Joining Intercept: a second FDA rejection already on the books44:16 - The complexity of liver biopsy endpoints compared to viral load45:42 - The advisory committee: "The odds were not in our favor"46:34 - Intercept sold to Alfasigma. Michelle steps away.47:46 - Advice to biotech teams: believe in your drug, stress test it, find the outliers50:19 - Is she done? "Richard thinks it's a sabbatical"50:54 - Mentoring young women in science51:46 - Closing reflections: when one door closes, another opportunity finds you

    53 min

  4. May 15

    What $12 Billion in Biotech Exits Taught This CEO About Relationships, Risk, and Near-Death

    What does it actually take to build a biotech from nothing... no IP, no programs, no money — into a company acquired by Eli Lilly for over $3 billion? In this episode of No Spotlight Needed, host Sheetal sits down with Praveen Tipirneni — engineer, physician, and military-trained biotech CEO who built Morphic Therapeutic over nine years, nearly died from an out-of-hospital cardiac arrest midway through, and still came back to close one of biotech's biggest deals of 2024. Now he's doing it again with Caldera Therapeutics. What we cover: - Why he sold before Phase 2B data — and the real math behind that call - Walking into his second board meeting ready to blow up the portfolio and get fired - Why people invest in people, not science — and the relationships that built every round - His no-PowerPoint writing culture (yes, before Bezos) - Why slowing down was always his instinct — and why it worked - The Friday the stock dropped 30% and the cardiac arrest that followed - His honest skepticism about AI in drug discovery - What drew him back to build Caldera Let’s connect: LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/ Connect with Praveen: https://www.linkedin.com/in/praveen-tipirneni-42a1a5/ Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 - Teaser: almost dying, relationships, and the stock drop Friday 0:40 - Intro: Praveen Tipirneni and the $3B Lilly acquisition 2:13 - Why sell Morphic before Phase 2B data? 3:06 - IBD isn't a disease a small company can commercialize 3:58 - The Olympics ad break analogy 5:41 - Not wanting to be CEO at 45 6:46 - The mentor who said "this is your window"8:26 - First six months at Morphic: sensing something was wrong 9:24 - "I don't just dislike our portfolio — I hate it" 10:47 - Starting from scratch: no IP, no programs, no money 13:13 - Why raising capital is all about relationships 14:26 - "Any biotech is a leap of faith. People invest in people." 15:02 - The Nils story: said no at Series A, led Series B 15:40 - Rajiv at Fidelity and how that relationship made the IPO 16:19 - The mistake: only calling investors when you're raising 17:13 - Morphic's use of Schrödinger and computational chemistry 19:39 - Why Praveen is an AI skeptic in drug discovery 21:50 - Building Morphic's culture: serious, deliberate, written 23:03 - The no-PowerPoint philosophy — before Bezos 25:28 - Tech vs. biotech: why "move fast" doesn't work here 28:22 - Being a conservative CEO — raising less than he could 29:02 - Letting people own their domains: the CFO story 33:25 - The cardiac arrest: stock drop, investor calls, and then nothing 35:30 - Two more arrests by Tuesday. Doctors said he wouldn't survive. 37:20 - "I should have died that day. Every day is not guaranteed." 38:47 - Why hiring great people meant the company ran without him 40:07 - The "break" that didn't last — and what pulled him back in 41:46 - Why he hired no one he knew for the first 2-3 years 43:21 - Cubist: joining a company at negative enterprise value 45:40 - What failures can you point to? 47:58 - CEO vs. Chairman: why they should always be separate 49:04 - Advice to founders: "It's never about the data" 50:46 - Life at Caldera: team-building, wearing every hat 53:18 - IPO as competitive moat and branding event 54:30 - Is biotech a race? What China has changed 54:48 - Free time: racing up mountains and everyone telling him to act his age 55:36 - Closing reflections

    55 min

  5. May 1

    Former CEO Explains How to Build a Forever Company With Culture That STICKS!

    Welcome to Season 2 of No Spotlight Needed! Episode 1 features Bruce Cozadd, former CEO of Jazz Pharmaceuticals. Bruce walks through the real moments behind building Jazz into a durable business, including what happened during the 2008 crash, how he thought about culture as the company scaled, why “bet the company” decisions need to be named out loud, and what it looks like to step away after a 20 plus year run without leaving a shadow behind. If you care about leadership, team building, and making hard calls with clarity, this one is a masterclass. What you’ll hear in this episode - What crisis leadership actually requires when people are scared - The “plan B, plan C, plan D” mindset that helped Jazz survive - A culture system that gives real signal, not lip service - When founders stay involved and when it hurts the new CEO - How to run succession without creating chaos Let’s connect:LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 Intro: why Jazz is “quietly different” 01:45 Building Jazz to create value without selling 04:49 Culture: defining it and making it measurable 06:06 Breakfast with Bruce: using new hires to gauge culture 08:02 Culture signals that actually matter (not slogans) 11:44 Founder staying involved: when it helps vs hurts 14:03 The danger of the old CEO “looking over your shoulder” 22:53 Going public: pros, cons, and ignoring the ticker 26:15 The 2008 to 2009 moment that almost ended Jazz 29:05 “Bet the company” decisions: name it out loud 30:14 Survival mode: cutting burn and reducing headcount 31:30 Mission and leadership: clarity, integrity, trust 41:09 Diversifying beyond one product: the long game 43:46 Measuring culture: surveys plus real employee comments 50:38 GW acquisition: criticism, conviction, and why it mattered 52:58 Retirement: how succession should work (without chaos)

    1h 4m

  6. Feb 9

    The $20M to $400M Scaling Blueprint | Dorothy Gemmell Interview

    In this Episode of No Spotlight Needed, Sheetal sits down with Dorothy Gemmell, a five time Chief Commercial Officer who helped scale multiple high growth healthcare businesses. No Spotlight Needed Website: https://www.nospotlightneeded.com/ Dorothy shares how she went from studying biochemistry at McGill University to pharmaceutical sales, then into leadership at 25, and eventually into the early internet era where she joined Medscape/WebMD as an early employee and helped scale revenue from about $20M to $400M+. You will hear her practical framework for hiring in fast growth environments, how to assess leaders in your first 90 days, when to remove toxic high performers, and why some of the best operators intentionally choose to stay in the number two seat. What you will learn: • Why early hires must include future leaders • The traits Dorothy screens for when hiring sales and commercial talent • A clear 90 day assessment process for leadership teams • Why toxicity has to go even if the person produces revenue • How Dorothy thinks about CEO strength vs CCO strength • The difference between VC, PE, and public company operating rhythms • How to preserve culture as headcount scales • Dorothy’s take on AI in healthcare and where it is already working Timestamps: 00:00 Dorothy introduced and leadership in high growth companies 00:29 When you know someone is the wrong person on the team 00:54 Why this conversation mattered to Sheetal 01:18 Dorothy’s early career and scaling experience preview 02:38 From pre med to business and pharma sales 03:15 Career day that changed her path 04:05 Why big company sales training matters 05:05 Why startups struggle to train people well 05:51 Becoming a district manager at 25 leading older reps 07:15 Leadership fundamentals and learning accountability 08:34 Why staying at a big company built her foundation 09:44 Lateral moves into marketing and international experience 10:58 Seeing the internet reshape healthcare and taking the leap 11:03 Why WebMD and Medscape felt like the future 12:08 Speeding up healthcare data and decisions via the internet 13:29 Joining Medscape early and loving the startup pace 15:06 Dot com volatility and leading through uncertainty 16:22 The balance between testing and burning cash 18:05 A blunt truth about job security in downturns 19:44 Hiring traits that scale teams in fast growth 21:12 Grit as a requirement in sales and startups 21:37 The 50 percent rule: hire people who can lead others 23:24 Numbers and accountability in commercial talent 24:39 Why she left WebMD and the noncompete lesson 26:19 CEOs do not need to know every job 27:27 The 90 day plan: change thoughtfully and fast 28:19 How Dorothy assesses leaders and teams 29:54 Toxicity has to go even when they are top performers 32:03 Set expectations early to reduce turmoil 33:24 The CEO traits that create loyalty and mission focus 36:11 Strategic discipline and avoiding the goat rodeo 36:53 Why Dorothy chooses to be number two 38:09 The personal cost of being CEO in growth companies 39:21 Work life balance: no guilt and being present 42:15 VC vs PE vs public: sprint marathon treadmill 44:14 Operating differences and resources by company type 46:16 Why she chose several smaller growth stints 48:05 Preserving culture as the company scales 50:09 C suite shifts: revenue plus margins and ops 51:14 What makes a strong executive team 52:29 Why offsites and relationship building matter 53:09 AI and the next chapter of healthcare 55:19 What she is most proud of: people she helped grow

    57 min

  7. Jan 30

    Building a $14B Lab Business: David King on CEO Development, Decisions & Culture at Scale

    Most people know LabCorp for routine blood work. But under CEO Dave King, the company expanded far beyond basic diagnostics, scaling from about $4B to $14B in revenue while navigating relentless pricing pressure, major acquisitions, and a rapidly changing healthcare landscape. In this conversation, Dave breaks down what it really takes to scale through M&A, why some deals worked and others missed expectations, and how to lead when decisions draw criticism. He also talks about Theranos, why he stayed quiet publicly, and how the science ultimately caught up. Finally, he shares how LabCorp built a unified, patient first culture across roles ranging from PhDs to couriers and phlebotomists, and why the team’s Covid response became one of his proudest moments. What you’ll hear in this episode: -The economics of the lab business and why volume matters -How Dave went from prosecutor and partner to LabCorp general counsel and then CEO -Building real compliance culture after a corporate integrity agreement -The biggest shift when you become CEO and why it takes time to learn the job -The “lazy with the numbers” moment and how it reshaped his leadership -LabCorp’s M&A strategy, including Genzyme Genetics and the Covance deal -Theranos behind the scenes and why LabCorp avoided taking the bait publicly -Navigating PAMA reimbursement cuts in a high fixed cost model-Succession, stepping away gracefully, and not becoming the “court of appeals” -How to build culture across a massive, diverse workforce -Why LabCorp’s Covid response is the moment he’s most proud of Timestamps: 00:00:00 LabCorp’s transformation and Dave King intro 00:01:10 The scale story: CEO tenure, growth, and deal reality 00:02:06 Early life: DC, Illinois, Berkeley 00:03:10 Princeton, public affairs, Near Eastern studies 00:03:32 Teaching high school and why he chose law 00:04:40 Traditional legal career: clerk, prosecutor, big firm 00:05:53 Meeting LabCorp through investigations 00:06:31 Why he moved in house and what changed personally 00:08:15 Compliance culture shift and staffing legal and compliance 00:09:23 Becoming CEO later in life and why that helped 00:11:31 The real CEO job versus ops leadership 00:13:09 “You’re lazy with the numbers” and the habit that fixed it 00:15:54 Strategy pivot: pricing pressure and broadening the revenue base 00:18:17 Genzyme Genetics and building leadership in genetics 00:20:23 Integration philosophy: one LabCorp culture 00:22:42 Deals you do not do and what he regrets not bolstering 00:24:52 Theranos: investor distraction, science reality, and why he stayed quiet 00:30:50 The Covance deal: why it mattered and the precision medicine thesis 00:33:10 Why Covance under delivered and what he learned 00:35:13 Leadership means decisions plus criticism 00:36:03 PAMA cuts: what happens in high fixed cost economics 00:39:06 Retirement planning and timing 00:40:35 Succession and stepping away gracefully 00:43:29 Not the court of appeals: how to support the new CEO 00:44:35 Culture across roles: scientists, couriers, phlebotomists 00:48:09 Senior team stability and deliberate hiring 00:49:47 Proud moments: the Covid response and the team’s intensity 00:52:19 Closing thoughts

    53 min

  8. Jan 23

    A CFO’s Playbook for Building Trust, Leading Through Crisis, and Driving Performance

    Many investors and operators call Mettler Toledo one of the best run companies in the world. In season 1, episode #3 of No Spotlight Needed, Sheetal sits down with Bill Donnelly, longtime CFO of Mettler Toledo, to unpack the leadership habits and cultural systems behind decades of consistent execution. Bill shares how his Jesuit foundation shaped his approach to communication, empathy, and decision making, why culture gets reinforced in moments of crisis, and what it really takes to sustain continuous improvement. He also reflects on the CEO-CFO relationship, how the Great Financial Crisis allowed them to move even faster, and why his next chapter is focused on mission-based education and social innovation at John Carroll University. Timestamps: Introduction to Bill Donnelly and Mettler Toledo (00:00:00) Overview of Mettler Toledo’s reputation, Bill Donnelly’s leadership, and his impact on company culture. Early Life and Family Background (00:02:38) Bill’s upbringing in New York and Chicago, Irish heritage, and influence of his grandfather. Education and Jesuit Foundation (00:05:20) Decision to attend John Carroll University, Jesuit values, and how education shaped his thinking and communication. Meeting His Wife and Early Career (00:11:28) Meeting his wife at John Carroll, early married life, and starting his career at Price Waterhouse. Lessons from Price Waterhouse (00:12:35) Technical and leadership skills developed, importance of international experience, and mentorship. First CFO Role at Elson Bailey (00:14:35) Transition to Elson Bailey, IPO experience, building company functions, and challenges of establishing culture. Joining Mettler Toledo and Swiss Culture (00:18:23) Introduction to Mettler Toledo, meeting Robert Sperry, and contrast between Swiss structure and previous roles. Transition to Operational Role in the US (00:21:10) Moving back to the US, running global inspection and lab businesses, and personal/professional development. Whistleblower Crisis at Mettler Toledo (00:22:51) Details of the whistleblower investigation, Bill’s return to stabilize the company, and impact on culture. Restoring Confidence and Leadership Tone (00:28:33) Setting the tone at the top, restoring trust, and reinforcing company values post-crisis. Family Crisis and Career Commitment (00:30:15) Wife’s cancer diagnosis, prioritizing family, and decision to remain at Mettler Toledo. CEO-CFO Leadership Dynamics (00:33:53) Relationship with CEOs Robert and Olivier, complementary skills, and building a strong leadership team. Navigating the Great Financial Crisis (00:40:01) Responding to the 2008 crisis, rapid cost-cutting, organizational resilience, and lessons learned. Continuous Improvement and Company Culture (00:46:33) How continuous improvement, humility, and trust drove Mettler Toledo’s long-term success. Retirement Decision and Succession (00:51:16) Reasons for retiring in 2018, preparing successors, and balancing personal and professional life. Mission at John Carroll University (00:53:53) Post-retirement focus on John Carroll University, leadership in education, and fostering social innovation. Conclusion and Reflections (00:58:24) Final thoughts on leadership, legacy, and gratitude for the opportunity to share his journey.

    1 hr

  9. Jan 16

    From Startup Failure to $1.2B Success: Erica Rogers on Culture, Resilience and Failing Fast

    In Season 1, episode #2 of No Spotlight Needed, host Sheetal Prasad sits down with Erica Rogers, board director and former CEO, to unpack the real story behind building and leading in MedTech, from her early career at Boston Scientific, to founding startups, navigating a company failure, and scaling Silk Road Medical through the public markets. Erica shares what it’s actually like when a clinical trial fails, how to lead a board to the hard decision to shut the doors, and why culture is not a poster on the wall, it’s a daily practice. She also explains the CEO reality nobody trains you for: making big calls with imperfect information, managing strong board personalities, and staying focused on building value. You’ll also hear the origin story of “Cartwheel Culture”, the framework Erica used to build a team people loved waking up to be a part of. Timestamps: Early Career and Upbringing (00:01:01) Erica’s childhood in San Diego, artistic background, and early influences. Big Company Training at Boston Scientific (00:03:12) Value of large company experience and cross-functional training. Transition to Entrepreneurship (00:04:51) Leaving Boston Scientific, being recruited, and the decision to pursue more impactful work. Entrepreneur in Residence and VizioJen (00:06:36) Role as entrepreneur in residence, partnering with Reza, and founding VizioJen in ophthalmology. Starting from Scratch and Early Startup Roles (00:08:08) Challenges of starting a company, learning new fields, and handling all responsibilities in a small team. VizioJen’s Exit and Personal Decisions (00:10:35) VizioJen’s $400M exit, personal reasons for leaving, and desire to start again. Founding Alex Medical and the Challenge of Failure (00:11:24) Formation of Alex Medical, novel ENT devices, and the excitement of new interventional procedures. Clinical Trial Failure and Company Closure (00:13:41) Failed clinical trial, economic downturn, and the difficult decision to shut down Alex Medical. Aftermath of Failure and Lessons Learned (00:16:40) Emotional impact of failure, value of company culture, and support from the team during wind-down. Navigating Doubt and Nonprofit Work (00:17:41) Dealing with founder doubt, working at Medicine360, and redefining success after failure. Joining Silk Road Medical (00:20:17) Recruitment to Silk Road, initial reluctance, and the principle of failing fast. Silk Road’s Early Culture and Team Rebuilding (00:22:36) Poor initial company culture, tough decisions, and rebuilding the team with a new vision. Hiring Strategy and Paradigm Shifts (00:25:16) Prioritizing talent, bringing in new perspectives, and the importance of domain expertise in key roles. Managing a Hands-On Board (00:29:14) Challenges of a strong, involved board, and learning that the company belongs to shareholders. IPO vs. Acquisition Decision (00:32:31) Weighing public offering against selling, emotional and practical considerations, and the drive to change medicine. Life as a Public Company CEO (00:37:10) Shifting responsibilities post-IPO, increased focus on investor relations, and reliance on a strong team. Reimbursement Challenges and Market Uncertainty (00:38:40) CMS reimbursement changes, market confusion, and the impact on Silk Road’s growth outlook. Retirement Decision and Succession (00:41:28) Achieving full coverage, planning retirement, and the optics of CEO transition amid business uncertainty. Reflecting on Silk Road’s Success (00:45:27) Boston Scientific’s acquisition, public perception of her exit, and pride in the company’s achievements. Cartwheel Culture and Company Values (00:46:22) Origin and meaning of “cartwheel culture,” its impact on team spirit, and embedding values in daily work. Next Chapter: Board Work and Personal Goals (00:50:23) Life after Silk Road, board roles, mentoring, community building, and pursuing personal passions like piano. Closing Remarks (00:52:14) Final thanks, reflections on impact, and advice for future entrepreneurs.

    53 min

  10. Jan 8

    4 Time CEO Keith Grossman on Turnarounds, Culture, and Boardroom Truths

    In Episode 1 of Season 1 of No Spotlight Needed, Sheetal sits down with Keith Grossman, a four time CEO and MedTech operator known for building and turning around companies through focus, urgency, and team first culture. Keith walks through the arc of his career, including becoming CEO of Thoratec at 35 with the company nearly out of cash, engineering a major merger to secure future technology, leading through the personal and organizational tragedy of 9/11, stepping away at the right time, and later returning to reignite execution and regain market share. They also dig into what makes boards helpful instead of harmful, why CEOs should not try to manage boards like a management team, and what Keith believes is the most repeatable lever in leadership: recruiting great people and creating energized cultures that win. What you’ll learn • How Keith prioritized when the company had almost no cash and everything was urgent • Why he pushed a merger even while winning near term market share • Leading through loss and keeping an organization steady in a crisis • The difference between growth through new customers vs getting to standard of care • Why decisive leadership and fewer projects often unlock performance fast • Board best practices for CEOs: collaboration, education, and honest dialogue • Keith’s “leadership superpower”: recruiting and building high performance cultures Timestamps: 00:00 Cold open: outcomes, what boards should do, and leadership focus 01:03 Intro to Keith: 4 time CEO, major exits, non linear path 02:16 Welcome + rapid fire begins 02:41 Where Keith was born and raised02:50 Parents and early influences 03:13 “Nothing happens until somebody sells something” 03:46 College path: Miami of Ohio to Ohio State04:17 Athlete, music, and team sports as leadership training 05:46 First jobs and earning early 06:30 Why Thoratec at 35 with $1M left and a massive challenge 08:56 Early priorities: capital raise, team, manufacturing, commercialization 10:44 Building the market while the plane is in the air 11:34 The hard truth: bridge to transplant market was too small 13:36 The merger strategy and why it worked 15:33 Negotiating control and why the deal was possible 17:37 The roller coaster: 9 11 and losing COO Tom Burnett on Flight 93 19:41 Leading through crisis: restructure and communicate immediately 21:40 Company mission and recovery 22:43 Why Keith initiated succession planning during a “magical” period 25:10 Results from first run at Thoratec 26:14 Joining TPG and learning the industry from the other side 28:34 Why Keith didn’t want to be a venture capitalist 29:08 Operator at heart 29:19 Taking the CEO role at Conceptus: why it was compelling 31:49 Diagnosis: growth stalled due to execution and culture 32:41 Fixing the model: standard of care vs chasing new customers 35:03 Fixing culture: urgency, analytics, accountability 36:04 Shrinking the sales force and returning to growth 37:33 The 1.1B exit and what came next 40:09 Watching Thoratec round trip and competitor pressure 43:04 The board asks Keith to return44:07 Coming back: moving faster with a ready playbook 45:49 Turnaround principle: vision, speed, and top down focus 47:55 Cutting initiatives, reorganizing leadership, reasserting customer value 49:21 Momentum returns fast50:32 The 3.4B sale and why consolidation made sense 53:39 Retirement, board work, and the next chapter 55:03 Nevro turnaround attempt and what Covid changed 01:01:32 Why the market may not have come back 01:03:29 Single product risk when growth stops 01:08:04 CEO advice on working with boards 01:11:22 What Keith is most proud of 01:13:31 Keith’s leadership “superpower”: recruiting + energized cultures 01:15:17 Closing

    1h 16m

  11. Trailer

    Introducing No Spotlight Needed, CEO Stories Beyond the Spotlight

    Welcome to No Spotlight Needed, a leadership podcast that explores the human stories behind extraordinary executives. Hosted by Sheetal Prasad, an equity investor with 25+ years of experience analyzing business models and assessing management teams, this show goes beyond the surface. These conversations focus on what rarely shows up in headlines or earnings calls: formative moments, values, decision making frameworks, and the principles that shape great leadership. This 90 second trailer is a montage from the first five episodes of Season 1, featuring lessons on leadership under pressure, culture that actually performs, board dynamics, and the real tradeoffs leaders make when the stakes are high. Season 1 lineup Keith Grossman, Retired CEO of Thoratec, Conceptus & Nevro, Board Member Erica Rogers, Retired CEO of Silk Road Medical, Entrepreneur, Board Member,  Bill Donnelly, Retired CFO of Mettler Toledo, Board Member David King, Retired Executive Chairman and CEO of Labcorp Dorothy Gemmell, 5X Chief Commercial Officer and President of GoodRx, Capsule, WebMD Trailer is live today, Thursday, January 8, 2026.Episode 1 with Keith Grossman goes live tomorrow, Friday, January 9, 2026. Listen, follow, and subscribe!

    2 min

Trailer

Ratings & Reviews

5
out of 5
12 Ratings

About

No Spotlight Needed is a leadership podcast that explores the human stories behind extraordinary executives. Through candid, in-depth conversations, CEOs and senior executives reveal the values, formative experiences, and decision-making frameworks that rarely make headlines but leave a lasting impact. These stories highlight critical lessons and management insights from today’s most effective business leaders. Whether you’re an aspiring leader, a seasoned executive, or simply curious about the intersection of character and business, this podcast offers clarity, humility, and practical wisdom

Information

  • Creator
    Sheetal Prasad
  • Years Active
    2K
  • Episodes
    11
  • Rating
    Clean
  • Copyright
    © Sheetal Prasad
  • Show Website
    No Spotlight Needed

You Might Also Like